Early Red Blood Cell Transfusion Strategy in Septic Shock Among Cancer Patients: Insights from the TRANSPORT Randomized Controlled Trial
Posted inClinical Updates Critical Care news Oncology

Early Red Blood Cell Transfusion Strategy in Septic Shock Among Cancer Patients: Insights from the TRANSPORT Randomized Controlled Trial

The TRANSPORT trial showed no superiority of liberal versus restrictive RBC transfusion in septic shock patients with cancer, highlighting no mortality benefit and increased thrombotic events with liberal strategy, underscoring the need for individualized transfusion approaches.
AI-Assisted Line-Field Confocal Optical Coherence Tomography for Early Detection of Subclinical Basal Cell Carcinoma: Current Evidence and Clinical Prospects
Posted inClinical Updates Dermatology news Oncology

AI-Assisted Line-Field Confocal Optical Coherence Tomography for Early Detection of Subclinical Basal Cell Carcinoma: Current Evidence and Clinical Prospects

This review examines emerging evidence on AI-assisted LC-OCT as a noninvasive, accurate tool for detecting subclinical basal cell carcinoma in high-risk patients, highlighting diagnostic performance, subtype classification, and translational implications.
Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
Posted inHematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.
Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Posted inHematology-Oncology news Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay for measurable residual disease assessment in real-world settings.